RegenXBio stock kpis
Want to see RGNX full AI Analyst Report?
Revenue by Segment
Analyzes income from different business units, highlighting which segments drive growth and profitability, and indicating potential areas for strategic focus or improvement.
Revenue is lumpy and milestone-driven: steady Zolgensma royalties historically provided a recurring base but collapsed in early‑2026, while licensing receipts (a large Nippon Shinyaku payment in 2025 and the $100M AbbVie milestone recognized in Q2‑2026) create outsized spikes. Management’s call confirms the AbbVie milestone; investors should treat near-term revenue as milestone-dependent and focus on sustainability of royalties, timing of future milestones, and regulatory risk that could delay expected cashflow from upcoming approvals.
RGNX Revenue by Segment
| Date | Zolgensma Royalties | Other License and Royalty | Nippon Shinyaku Licenses |
|---|---|---|---|
| Sep 30, 2026 | $5.24M | $0.00 | $0.00 |
| Jun 30, 2026 | $3.84M | $100.00M | $0.00 |
| Mar 31, 2026 | $5.05M | $38.00K | $0.00 |
| Dec 31, 2025 | $24.18M | -$2.09M | $204.00K |
| Sep 30, 2025 | $23.59M | $19.00K | $0.00 |
| Jun 30, 2025 | $18.42M | $216.00K | $2.72M |
| Mar 31, 2025 | $16.99M | $2.04M | $69.98M |
| Dec 31, 2024 | $20.66M | $558.00K | $0.00 |
| Sep 30, 2024 | $23.87M | $325.00K | $0.00 |
| Jun 30, 2024 | $21.76M | $532.00K | $0.00 |
| Mar 31, 2024 | $15.21M | $408.00K | $0.00 |
| Dec 31, 2023 | $21.86M | $348.00K | $0.00 |
| Sep 30, 2023 | $28.36M | $550.00K | $0.00 |
| Jun 30, 2023 | $18.96M | $1.01M | $0.00 |
| Mar 31, 2023 | $16.13M | $3.01M | $0.00 |
| Dec 31, 2022 | $26.79M | $4.56M | $0.00 |
| Sep 30, 2022 | $25.20M | $1.31M | $0.00 |
| Jun 30, 2022 | $28.39M | $4.26M | $0.00 |
| Mar 31, 2022 | $21.54M | $679.00K | $0.00 |
| Dec 31, 2021 | $28.03M | $622.00K | $0.00 |
| Sep 30, 2021 | $30.25M | $519.00K | $0.00 |
| Jun 30, 2021 | $18.43M | $3.61M | $0.00 |
| Mar 31, 2021 | $18.26M | $621.00K | $0.00 |

